| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
CARBOHYDRATE ANTIGEN 19-9 (CA 19-9), SERUM
MessagePotentially useful as adjunct for diagnosing and monitoring of pancreatic cancer. May be used for differentiating patients with
cholangiocarcinoma and primary sclerosing cholangitis (PSC) from those with PSC alone.
This test is NOT intended for screening of healthy/asymptomatic populations
cholangiocarcinoma and primary sclerosing cholangitis (PSC) from those with PSC alone.
This test is NOT intended for screening of healthy/asymptomatic populations
Test Code
LAB304384
CPT Codes
86301
Preferred Specimen
One 5 mL Gold top tube
Minimum Volume
2 mL blood
Other Acceptable Specimens
Red top tube, Dark Green top tube, and Light Green top tube
Instructions
Required for testing 2 mL blood. Avoid freeze-thaw cycling. Sample must be centrifuged within 2 hours of collection.
Serum must be removed from the red cells and put into aliquot tubes following centrifugation
Serum must be removed from the red cells and put into aliquot tubes following centrifugation
Specimen Stability
Centrifuge within 2 hours after collection Ambient: 24 hours Refrigerated: 7 days Frozen: unspecified
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Turbid, lipemic, grossly hemolyzed or heat-inactivated specimens. Cadaveric specimens or body fluids other than serum.
Methodology
Chemiluminescent Microparticle Immunoassay on Alinityi Upper limit of quantification: 360,000 U/mL
Reference Range
< 37 U/mL
Clinical Significance
Test potentially useful as adjunct for diagnosing and monitoring of pancreatic cancer. May be used for differentiating patients with
cholangiocarcinoma and primary sclerosing cholangitis (PSC) from those with PSC alone. This test is not intended for screening of healthy/asymptomatic populations. Smoking increases serum CA 19-9 levels. CA 19-9 may be elevated in
patients with nonmalignant diseases including rectal polyps, diabetes, cirrhosis, hepatitis, other GI diseases and renal disease.
Lewis negative patients (5-7% of patients) do not express CA 19-9 due to the lack of the enzyme fucosyltransferase needed for CA 19-9
production. In these individuals, a low or undetectable serum CA 19-9 concentration is not informative regarding cancer recurrence despite
having a disease associated with elevated CA 19-9 levels.
cholangiocarcinoma and primary sclerosing cholangitis (PSC) from those with PSC alone. This test is not intended for screening of healthy/asymptomatic populations. Smoking increases serum CA 19-9 levels. CA 19-9 may be elevated in
patients with nonmalignant diseases including rectal polyps, diabetes, cirrhosis, hepatitis, other GI diseases and renal disease.
Lewis negative patients (5-7% of patients) do not express CA 19-9 due to the lack of the enzyme fucosyltransferase needed for CA 19-9
production. In these individuals, a low or undetectable serum CA 19-9 concentration is not informative regarding cancer recurrence despite
having a disease associated with elevated CA 19-9 levels.
Performing Laboratory
West Virginia University Hospital, Inc.
Princeton Community Hospital
